C3.ai, Inc. AI closed fiscal 2025 with strong momentum, positioning its Generative AI and agentic AI platforms as central ...

Following a barrage of letters from President Donald Trump urging 17 large pharmaceutical companies to implement Most Favored ...

Gilead Sciences generates stellar profit margins with its HIV and hepatitis C virus, or HCV, portfolio, which requires only a small salesforce and inexpensive manufacturing. We think its portfolio and ...

US healthcare stocks struggle in 2025 due to government policies, sparking interest from bargain hunters as valuations reach ...

Key Points GAAP revenue surged to $66.8 million in Q2 2025, driven by recognition of one-time license and milestone payments, exceeding analyst estimates by 3,065.9% (GAAP). GAAP loss per share ...

Key Points On July 22, 2025, the U.S. Food and Drug Administration issued a Complete Response Letter for RP1, delaying potential commercialization and revenue. Research and development expenses ...

Covenant Health is now offering CAR T-cell therapy at the Joe Arrington Cancer Research & Treatment Center, marking a major ...

Patients with inflammatory bowel disease (IBD) have a 48% greater relative risk of developing interstitial lung disease (ILD) ...